APO RESEARCH · REPORT
Gene Therapy
Gene therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. Researchers are studying gene therapy for a number of diseases, such as severe combined immuno-deficiencies, hemophilia, Parkinson's disease, cancer and even HIV, through a number of different approaches. A gene can be delivered to a cell using a carrier known as a “vector.” The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy.
Product & engineering
Understand the product.
Gene therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. Researchers are studying gene therapy for a number of diseases, such as severe combined immuno-deficiencies, hemophilia, Parkinson's disease, cancer and even HIV, through a number of different approaches. A gene can be delivered to a cell using a carrier known as a “vector.” The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy.
Selected research
Industry Research
Gene Therapy Industry Research Report 2026
Market perspective
Gene therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. Researchers are studying gene therapy for a number of diseases, such as severe combined immuno-deficiencies, hemophilia, Parkinson's disease, cancer and even HIV, through a number of different approaches. A gene can be delivered to a cell using a carrier known as a “vector.” The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy.
Global Gene Therapy key players include Biogen, Novartis, Gilead Sciences, etc. Global top three manufacturers hold a share about 75%.
North America is the largest market, with a share about 60%, followed by Europe and Asia-Pacific, both have a share about 35 percent.
Read the full market overview
In terms of product, Non-viral Gene Therapy is the largest segment, with a share about 55%. And in terms of application, the largest application is Neurological Diseases, followed by Cancer.
Report Scope
This report quantifies the global Gene Therapy market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Gene Therapy.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gene Therapy Market by Company
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Gene Therapy Segment by Type
Viral Gene Therapy
Non-Viral Gene Therapy
Gene Therapy Segment by Application
Neurological Diseases
Cancer
Other
Gene Therapy Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Gene Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Viral Gene Therapy
- Non-Viral Gene Therapy
Applications
- Neurological Diseases
- Cancer
- Other
Companies covered
- Biogen
- Novartis
- Gilead Sciences
- Sarepta Therapeutics
- Alnylam Pharmaceuticals
- Amgen
- Spark Therapeutics
- Akcea Therapeutics
- bluebird bio
- Sunway Biotech
- SIBIONO
- AnGes
- Orchard Therapeutics
- Human Stem Cells Institute
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Gene Therapy by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Viral Gene Therapy
- 2.2.3 Non-Viral Gene Therapy
- 2.3 Gene Therapy by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Neurological Diseases
- 2.3.3 Cancer
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Gene Therapy Breakdown Data by Type
- 3.1 Global Gene Therapy Historic Market Size by Type (2021-2026)
- 3.2 Global Gene Therapy Forecasted Market Size by Type (2027-2032)
4 Gene Therapy Breakdown Data by Application
- 4.1 Global Gene Therapy Historic Market Size by Application (2021-2026)
- 4.2 Global Gene Therapy Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Gene Therapy Market Perspective (2021-2032)
- 5.2 Global Gene Therapy Growth Trends by Region
- 5.2.1 Global Gene Therapy Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Gene Therapy Historic Market Size by Region (2021-2026)
- 5.2.3 Gene Therapy Forecasted Market Size by Region (2027-2032)
- 5.3 Gene Therapy Market Dynamics
- 5.3.1 Gene Therapy Industry Trends
- 5.3.2 Gene Therapy Market Drivers
- 5.3.3 Gene Therapy Market Challenges
- 5.3.4 Gene Therapy Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Gene Therapy Players by Revenue
- 6.1.1 Global Top Gene Therapy Players by Revenue (2021-2026)
- 6.1.2 Global Gene Therapy Revenue Market Share by Players (2021-2026)
- 6.2 Global Gene Therapy Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Gene Therapy Head Office and Area Served
- 6.4 Global Gene Therapy Players, Product Type & Application
- 6.5 Global Gene Therapy Manufacturers Established Date
- 6.6 Global Gene Therapy Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Gene Therapy Market Size (2021-2032)
- 7.2 North America Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Gene Therapy Market Size by Country (2021-2026)
- 7.4 North America Gene Therapy Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Gene Therapy Market Size (2021-2032)
- 8.2 Europe Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Gene Therapy Market Size by Country (2021-2026)
- 8.4 Europe Gene Therapy Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Gene Therapy Market Size (2021-2032)
- 9.2 Asia-Pacific Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Gene Therapy Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Gene Therapy Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Gene Therapy Market Size (2021-2032)
- 10.2 South America Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Gene Therapy Market Size by Country (2021-2026)
- 10.4 South America Gene Therapy Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Gene Therapy Market Size (2021-2032)
- 11.2 Middle East & Africa Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Gene Therapy Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Gene Therapy Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Biogen
- 12.1.1 Biogen Company Information
- 12.1.2 Biogen Business Overview
- 12.1.3 Biogen Revenue in Gene Therapy Business (2021-2026)
- 12.1.4 Biogen Gene Therapy Product Portfolio
- 12.1.5 Biogen Recent Developments
- 12.2 Novartis
- 12.2.1 Novartis Company Information
- 12.2.2 Novartis Business Overview
- 12.2.3 Novartis Revenue in Gene Therapy Business (2021-2026)
- 12.2.4 Novartis Gene Therapy Product Portfolio
- 12.2.5 Novartis Recent Developments
- 12.3 Gilead Sciences
- 12.3.1 Gilead Sciences Company Information
- 12.3.2 Gilead Sciences Business Overview
- 12.3.3 Gilead Sciences Revenue in Gene Therapy Business (2021-2026)
- 12.3.4 Gilead Sciences Gene Therapy Product Portfolio
- 12.3.5 Gilead Sciences Recent Developments
- 12.4 Sarepta Therapeutics
- 12.4.1 Sarepta Therapeutics Company Information
- 12.4.2 Sarepta Therapeutics Business Overview
- 12.4.3 Sarepta Therapeutics Revenue in Gene Therapy Business (2021-2026)
- 12.4.4 Sarepta Therapeutics Gene Therapy Product Portfolio
- 12.4.5 Sarepta Therapeutics Recent Developments
- 12.5 Alnylam Pharmaceuticals
- 12.5.1 Alnylam Pharmaceuticals Company Information
- 12.5.2 Alnylam Pharmaceuticals Business Overview
- 12.5.3 Alnylam Pharmaceuticals Revenue in Gene Therapy Business (2021-2026)
- 12.5.4 Alnylam Pharmaceuticals Gene Therapy Product Portfolio
- 12.5.5 Alnylam Pharmaceuticals Recent Developments
- 12.6 Amgen
- 12.6.1 Amgen Company Information
- 12.6.2 Amgen Business Overview
- 12.6.3 Amgen Revenue in Gene Therapy Business (2021-2026)
- 12.6.4 Amgen Gene Therapy Product Portfolio
- 12.6.5 Amgen Recent Developments
- 12.7 Spark Therapeutics
- 12.7.1 Spark Therapeutics Company Information
- 12.7.2 Spark Therapeutics Business Overview
- 12.7.3 Spark Therapeutics Revenue in Gene Therapy Business (2021-2026)
- 12.7.4 Spark Therapeutics Gene Therapy Product Portfolio
- 12.7.5 Spark Therapeutics Recent Developments
- 12.8 Akcea Therapeutics
- 12.8.1 Akcea Therapeutics Company Information
- 12.8.2 Akcea Therapeutics Business Overview
- 12.8.3 Akcea Therapeutics Revenue in Gene Therapy Business (2021-2026)
- 12.8.4 Akcea Therapeutics Gene Therapy Product Portfolio
- 12.8.5 Akcea Therapeutics Recent Developments
- 12.9 bluebird bio
- 12.9.1 bluebird bio Company Information
- 12.9.2 bluebird bio Business Overview
- 12.9.3 bluebird bio Revenue in Gene Therapy Business (2021-2026)
- 12.9.4 bluebird bio Gene Therapy Product Portfolio
- 12.9.5 bluebird bio Recent Developments
- 12.10 Sunway Biotech
- 12.10.1 Sunway Biotech Company Information
- 12.10.2 Sunway Biotech Business Overview
- 12.10.3 Sunway Biotech Revenue in Gene Therapy Business (2021-2026)
- 12.10.4 Sunway Biotech Gene Therapy Product Portfolio
- 12.10.5 Sunway Biotech Recent Developments
- 12.11 SIBIONO
- 12.11.1 SIBIONO Company Information
- 12.11.2 SIBIONO Business Overview
- 12.11.3 SIBIONO Revenue in Gene Therapy Business (2021-2026)
- 12.11.4 SIBIONO Gene Therapy Product Portfolio
- 12.11.5 SIBIONO Recent Developments
- 12.12 AnGes
- 12.12.1 AnGes Company Information
- 12.12.2 AnGes Business Overview
- 12.12.3 AnGes Revenue in Gene Therapy Business (2021-2026)
- 12.12.4 AnGes Gene Therapy Product Portfolio
- 12.12.5 AnGes Recent Developments
- 12.13 Orchard Therapeutics
- 12.13.1 Orchard Therapeutics Company Information
- 12.13.2 Orchard Therapeutics Business Overview
- 12.13.3 Orchard Therapeutics Revenue in Gene Therapy Business (2021-2026)
- 12.13.4 Orchard Therapeutics Gene Therapy Product Portfolio
- 12.13.5 Orchard Therapeutics Recent Developments
- 12.14 Human Stem Cells Institute
- 12.14.1 Human Stem Cells Institute Company Information
- 12.14.2 Human Stem Cells Institute Business Overview
- 12.14.3 Human Stem Cells Institute Revenue in Gene Therapy Business (2021-2026)
- 12.14.4 Human Stem Cells Institute Gene Therapy Product Portfolio
- 12.14.5 Human Stem Cells Institute Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst